Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Adkins

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Cancers|February 13, 2025
Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 TrialPeter J Oppelt, Sidharth V Puram, Jingxia Liu, et al.
Cancers|November 13, 2025
Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 TrialPeter Oppelt, Jessica Ley, Christine Auberle, et al.
Oral Oncology|December 16, 2014
Looking beyond the CRT paradigm: why induction chemotherapy is worthy of pursuitDouglas Adkins, Jessica Ley, Loren Michel, et al.
Oral Oncology|January 19, 2021
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trialPeter Oppelt, Jessica C Ley, Francis Worden, et al.
Cancer Medicine|January 12, 2026
Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaDouglas Adkins, Jessica C Ley, Christine Auberle, et al.
Oral Oncology|July 20, 2014
Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neckWaseem Touma, Sami S Koro, Jessica Ley, et al.
Head & Neck|December 12, 2018
Outcomes of relapsed human papillomavirus-related oropharyngeal squamous cell carcinoma treated with curative intentPatrik Pipkorn, Parul Sinha, Dorina Kallogjeri, et al.
JCO Oncology Practice|April 18, 2025
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical InsightsRyan Li, Jamie A Ku, Douglas Adkins, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical InsightsRyan Li, Jamie A Ku, Douglas Adkins, et al.
Head & Neck|December 19, 2015
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neckDanny Rischin, David R Spigel, Douglas Adkins, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Cancers|February 13, 2025
Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 TrialPeter J Oppelt, Sidharth V Puram, Jingxia Liu, et al.
Cancers|November 13, 2025
Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 TrialPeter Oppelt, Jessica Ley, Christine Auberle, et al.
Oral Oncology|December 16, 2014
Looking beyond the CRT paradigm: why induction chemotherapy is worthy of pursuitDouglas Adkins, Jessica Ley, Loren Michel, et al.
Oral Oncology|January 19, 2021
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trialPeter Oppelt, Jessica C Ley, Francis Worden, et al.
Cancer Medicine|January 12, 2026
Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaDouglas Adkins, Jessica C Ley, Christine Auberle, et al.
Oral Oncology|July 20, 2014
Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neckWaseem Touma, Sami S Koro, Jessica Ley, et al.
Head & Neck|December 12, 2018
Outcomes of relapsed human papillomavirus-related oropharyngeal squamous cell carcinoma treated with curative intentPatrik Pipkorn, Parul Sinha, Dorina Kallogjeri, et al.
JCO Oncology Practice|April 18, 2025
Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical InsightsRyan Li, Jamie A Ku, Douglas Adkins, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline Clinical InsightsRyan Li, Jamie A Ku, Douglas Adkins, et al.
Head & Neck|December 19, 2015
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neckDanny Rischin, David R Spigel, Douglas Adkins, et al.
Pageof 9